Tim Greaney

Thomas (Tim) Greaney, JD, is a Visiting Professor of Law at UC Hastings College of Law in San Francisco and Distinguished Senior Fellow with the UC Hastings/UCSF Consortium on Law, Science & Health Policy. He is also Chester A. Myers Emeritus Professor of Law at Saint Louis University School of Law where he served as Director of the Center for Health Law Studies. His research focuses on the application of antitrust law to the health care sector, health care financing, and health care law and policy. He has written over 60 scholarly articles and chapters and is co-author of the nation’s leading health law casebook, HEALTH LAW: CASES, MATERIALS AND PROBLEMS (West, 8th edition 2018) and a treatise on health law, HEALTH LAW (WEST 3RD ED. 2014). He has testified on health care competition issues before the Judiciary Committees of the United States Senate and House of Representatives, the California Department of Insurance, and has spoken at workshops of the Federal Trade Commission. He has commented on health policy and law issues in the New York Times, Wall Street Journal and many other publications. Before entering academia, he served as an Assistant Chief in the U.S. Department of Justice Antitrust Division, supervising health care antitrust litigation. Professor Greaney has been named Health Law Professor of the Year by the American Society of Law and Medicine and has been a Fulbright Fellow studying European Community competition law in Brussels, Belgium. He received his B.A. from Wesleyan University and his J.D. from Harvard Law School.

Invigorating Competition in Health Care Markets: Is Rate Regulation Needed?

It now appears that market concentration may be the leading cause of America’s health care cost crisis. If the United States is...

Latest news

The NCAA Goes After College Athletes’ NIL Money—Here are the Antitrust Implications for Workers and Consumers

Having lost in the Supreme Court on student-athlete academic benefits, the NCAA has signaled a continuing attempt to suppress competition in the...

Have Business Roundtable Companies Lived Up to Their Stakeholder Commitments?  

In 2019, more than 100 CEOs of US public companies signed a Business Roundtable statement in which they pledged to deliver value...

Do Protests Matter At All for Shifting Government Policy Around Economic Redistribution?

New research on the effectiveness of protests on government distributions provides insights into the political incentives of a country’s leadership and the...

Mergers and Smoking Guns

A recently uncovered memo from George Stigler and Richard Posner reveals how they thought about antitrust and merger policy in advising the...

Will “Portfolio Primacy” Throw a Monkey Wrench in Elon Musk’s Plans to Acquire Twitter?

The SEC's definition of fiduciary duty allows institutional shareholders to vote against Elon Musk's Twitter takeover bid thanks to portfolio primacy.

How Europe Can Enforce the Digital Markets Act Effectively 

As the European Commission gets ready to embark on the complicated task of implementing the recently agreed-upon Digital Market Act, which would...

How Enlightened is Enlightened Shareholder Value?

There has been growing support for replacing the traditional corporate purpose with so-called “enlightened shareholder value,” which would guide firms to consider...